UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000049251
Receipt number R000056073
Scientific Title Study of usefulness of ePRO in cardiovascular disease
Date of disclosure of the study information 2022/10/19
Last modified on 2023/10/20 22:12:30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of usefulness of ePRO in cardiovascular disease

Acronym

Study of usefulness of ePRO in cardiovascular disease

Scientific Title

Study of usefulness of ePRO in cardiovascular disease

Scientific Title:Acronym

Study of usefulness of ePRO in cardiovascular disease

Region

Japan


Condition

Condition

cardiovascular disease

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine whether visualizing patient symptoms with electric patient-reported outcomes (ePRO) for patients with cardiovascular disease improves patient satisfaction.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Satisfaction using Likert scale

Key secondary outcomes

Assessment of patient well-being, and patient preferences for shared decision making using questionnaires


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Other

Interventions/Control_1

After explaining the research, consent will be obtained with an electronic signature. After that, you will be asked to answer 1 pre-questionnaire in writing, a total of 5 questionnaires on ePRO, and 1 post-questionnaire in writing at the end of the observation.

Interventions/Control_2

After explaining the research, consent will be obtained with an electronic signature. After that, you will be asked to answer one written pre-questionnaire and one written post-questionnaire at the end of the observation.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.Adults over 18 years of age with outpatient cardiovascular disease
2. Previous catheterization for angina pectoris/myocardial infarction, heart failure meeting the Framingham criteria and (at enrollment) BNP >100 pg/ml on blood draw, atrial Patients with atrial fibrillation detected by 12-lead ECG

Key exclusion criteria

1.Patients who are judged to be inappropriate for this study by the research representative/co-investigators
2.Patients who cannot operate electronic devices such as tablets

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Jinzaki
Middle name
Last name Masahiro

Organization

Keio University

Division name

School of Medicine, Department of Diagnostic Radiology

Zip code

160-0016

Address

35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582 Japan

TEL

03-3353-1211

Email

jinzaki@rad.med.keio.ac.jp


Public contact

Name of contact person

1st name Katsumata
Middle name
Last name Yoshinori

Organization

Keio University

Division name

School of Medicine, Institute for Integrated Sports Medicine

Zip code

160-0016

Address

35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582 Japan

TEL

03-5269-9054

Homepage URL


Email

goodcentury21@keio.jp


Sponsor or person

Institute

Keio University

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Keio University School of Medicine

Address

35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582 Japan

Tel

03-5363-3503

Email

med-rinri-jimu@adst.keio.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

産業医科大学(福岡県)、日野市立病院(東京都)、国立病院機構埼玉病院(埼玉県)


Other administrative information

Date of disclosure of the study information

2022 Year 10 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

50

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2022 Year 10 Month 06 Day

Date of IRB

2022 Year 10 Month 14 Day

Anticipated trial start date

2022 Year 11 Month 04 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 10 Month 18 Day

Last modified on

2023 Year 10 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056073


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name